To the Editor-Molina et al. [1] showed good efficacy and safety of once-daily antiretroviral combination (ARV) therapy during the 24 first weeks of treatment with emtricitabine, didanoside, and efavirenz among 40 patients who were naive to treatment. Ease of administration of once-daily dosing represents a considerable advance in the quality of life of human immunodeficiency virus (HIV)-infected patients. Molina et al. investigated oncedaily highly active antiretroviral therapy regimens as a means of optimizing treatment adherence. However, the impact of oncedaily treatment on adherence is not clear from the medical literature.
